

From: Liverpool-ECMC
Sent: 04 March 2020 16:42
To: Liverpool-ECMC
Subject: Liverpool ECMC Newsletter March 2020 - Haematology

Follow Up Flag: Follow up
Flag Status: Completed

LIVERPOOL ECMC NEWSLETTER **MARCH 2020** *HAEMATOLOGY*



ASTRAZENECA JUNIOR INVESTIGATOR MEETING 20TH- 21ST MARCH 2020

AstraZeneca are hosting a Junior Investigator meeting on Friday 20th and Saturday 21st March 2020 in the Malmaison, Manchester.

This meeting is aimed at healthcare professionals who have a clear focus on oncology or immunology, and an interest in actively contributing to clinical and translational research in the UK.

The meeting will address a range of clinical research applications including cancer biology, screening, prevention and diagnosis, with the agenda made up of sessions that focus on the design and performance of oncology-related clinical research as well as methods of data and statistical analysis.

Please click [here](#) to download the agenda.

Information on how to register can be found [here](#).

SHEFFIELD ECMC BONE ONCOLOGY WORKSHOP - FRIDAY 5TH JUNE 2020



Sheffield ECMC is running a free **ECMC Bone Oncology Workshop in Sheffield on Friday 5th June 2020**. The exciting programme includes short talks from world leaders in the bone oncology field who will address the issues of who to treat, when to treat and with what.

The workshop is suitable for all clinicians and researchers with an interest in gaining a better understanding of bone oncology.

Please contact [Caroline Potts](#) to register.



INAUGURAL ECMC LIQUID BIOPSY FORUM - FRIDAY 22ND MAY 2020

The Inaugural ECMC Liquid Biopsy Forum will be held on 22nd May at the Alderley Park Conference Centre.

The forum will focus on ECMC network collaborations involving liquid biopsies and a more detailed assessment of the technical and logistical challenges in this pursuit.

More information and how to register can be found [here](#).



NEW EARLY PHASE TRIALS COMING SOON

PORT is for patients with mycosis fungoides or sezary syndrome who have relapsed / are refractory after at least 1 prior systemic therapy. It offers a combination of pembrolizumab and radiotherapy.

BI-1206 is for all patients with a CD32b+ B cell malignancy or CLL, who are relapsed/refractory to conventional treatments, or for whom no conventional therapy exists, or has been declined by the patient.

It uses rituximab in combination with anti-CD32b for treatment over 4 weeks with maintenance over another year if the patient responds.

Please contact **Jane Tinsley** for potential referral to these trials.

OPEN TRIALS

Please contact **Jane Tinsley** for potential referral to these trials.

- Telephone: 0151 706 4886



- **HARMONY** – A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- **HERACLES** – Treatment of steroid refractory gastro-intestinal acute graft-versus-Host disEase after Allogeneic hematopoietic stem cell transplantation with faecal microbiota transfer
- **MANIFEST** – A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with

Haematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)

- **TIDaL** – Risk-stratified sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-novo post-transplant Lymphoproliferative disorder (PTLD)

[Find out more...](#)

EVENTS & JOB OPPORTUNITIES

EVENTS

- **[AstraZeneca Junior Investigator Meeting \(20TH-21ST MARCH 2020\)](#)**
- **[Sheffield ECMC Bone Oncology Workshop \(5TH JUNE 2020\)](#)**
- **<https://www.ecmcnetwork.org.uk/events>**

JOB OPPORTUNITIES

- **[Advanced Research Practitioner - Clatterbridge Cancer Centre NHS Foundation Trust - Grade 7 - Closing Date: 5th March 2020 \(1\)](#)**
- **[Advanced Research Practitioner - Clatterbridge Cancer Centre NHS Foundation Trust - Grade 7 - Closing Date: 5th March 2020 \(2\)](#)**
- **[Senior Trials Manager - University of Liverpool - Grade 8 - Closing Date: 20th March 2020](#)**

CONTACT US

If you require any information which isn't on the newsletter please contact the Liverpool ECMC Team via **[e-mail](#)**.

Copyright © 2019 Liverpool ECMC, All rights reserved.

Our mailing address is:

livecmc@liv.ac.uk